Avirmax Biopharma Showcases Innovative Research at ARVO 2026 Meeting#United_States#Avirmax_Biopharma#Denver#gene_therapy#ARVO
Avirmax Biopharma Showcases Innovative Research at ARVO 2026 Meeting
Avirmax Biopharma Inc. will present groundbreaking findings at the ARVO 2026 Annual Meeting, focusing on ocular gene therapy advancements and innovations in vector genome determination.
third-news.com
April 27, 2026 at 3:44 PM
Avirmax Biopharma Showcases Innovative Research at ARVO 2026 Meeting#United_States#Avirmax_Biopharma#Denver#gene_therapy#ARVO
Avirmax Biopharma Inc. Showcases Groundbreaking Research at the ARVO 2025 Annual Meeting#Avirmax_Biopharma#AAV_Gene_Therapy#Dry_AMD
Avirmax Biopharma Inc. Showcases Groundbreaking Research at the ARVO 2025 Annual Meeting
Avirmax Biopharma is set to make a significant impact at the 2025 ARVO meeting with multiple presentations focused on ocular gene therapy advancements through its proprietary technologies.
third-news.com
April 23, 2025 at 8:48 PM
Avirmax Biopharma Inc. Showcases Groundbreaking Research at the ARVO 2025 Annual Meeting#Avirmax_Biopharma#AAV_Gene_Therapy#Dry_AMD
Avirmax Biopharma Launches Pioneering Gene Therapy Studies for Age-related Macular Degeneration#United_States#Avirmax_Biopharma#gene_therapy#Hayward,_California#ABI-201
Avirmax Biopharma Launches Pioneering Gene Therapy Studies for Age-related Macular Degeneration
Avirmax Biopharma begins pivotal studies for ABI-201, a groundbreaking gene therapy aimed at treating dry age-related macular degeneration and preserving vision.
third-news.com
February 28, 2025 at 6:59 PM
Avirmax Biopharma Launches Pioneering Gene Therapy Studies for Age-related Macular Degeneration#United_States#Avirmax_Biopharma#gene_therapy#Hayward,_California#ABI-201
Avirmax Biopharma Reaches Key Milestone with ABI-110 Clinical Trial Enrollment Completion#USA#Avirmax_Biopharma#Wet_AMD#ABI-110#Hayward
Avirmax Biopharma Reaches Key Milestone with ABI-110 Clinical Trial Enrollment Completion
Avirmax Biopharma has successfully completed the first cohort of patient enrollment for its ABI-110 clinical trial targeting Wet AMD and PCV, marking a significant milestone.
third-news.com
February 3, 2025 at 1:12 PM
Avirmax Biopharma Reaches Key Milestone with ABI-110 Clinical Trial Enrollment Completion#USA#Avirmax_Biopharma#Wet_AMD#ABI-110#Hayward
Avirmax Biopharma Launches Groundbreaking Gene Therapy Trial for Wet AMD#USA#Avirmax_Biopharma#Wet_AMD#ABI-110#Hayward
Avirmax Biopharma Launches Groundbreaking Gene Therapy Trial for Wet AMD
Avirmax Biopharma has commenced the Phase I/IIa trial of ABI-110, a pioneering gene therapy targeting Wet Age-related Macular Degeneration and PCV.
third-news.com
November 22, 2024 at 11:15 AM
Avirmax Biopharma Launches Groundbreaking Gene Therapy Trial for Wet AMD#USA#Avirmax_Biopharma#Wet_AMD#ABI-110#Hayward